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Introduction :  
Surgical debulking with perioperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) is an established treatment 
option in selected patients with peritoneal carcinomatosis. When oxaliplatin is used as the chemotherapeutic drug, 
patients develop a metabolic disorder with severe hyponatremia , hyperglycemia and hyperlactatemia (1). The exact 
pathogenesis of the hyperglycemia is not entirely understood in the context of complex peritoneal transport after 
extensive surgical trauma (2) and changing perioperative glucose handling of the body (3). But as Perioperative 
hyperglycemia is associated with worse outcome.(3) we wanted to test the hypothesis that the temperature of the 
dialysate has an influence on the hyperglycemia, one of the driving factors of this clinical picture. 
Materials and Methods :  
Between july 2005 and june 2010, 118 patients were treated with oxaliplatin based HIPEC in our tertiary centre. During the 
30minute perfusion, temperature was continuously recorded at 3 sites. Repeated bloodgas analysis was performed at the 
start (t0), at 15 minutes (t15) and at the end of the perfusion (t30). Patient charts were analyzed and demographic data 
were included in the analysis. A stepwise multiple regression analysis was performed to predict the glycemia at t15 and 
t30. 
Results:  
At t15 and t30 a weak but significant model could be constructed. After 15 minutes two factors were withheld by the 
model; the glycemia at the beginning of the perfusion and maximum temperature during this period. At the end of the 
perfusion, t30 only the glycemia at the beginning of the HIPEC was an independent variable. Full reports of the two 
analysis are given in table 1 and table 2 
 
Table 1: Multiple regression analysis report at t15  
R² adjusted = 0,118; F(2,107) = 8,31 ; p<0,001; constant coefficient: -590,00 
Independent variable  Stand Err P –value 
Glycemia at t0 0,60 0,20 0,003 
Maximal temperature after 15 minutes 20,37 7,28 0,006 
Not included in the model 
  BMI 
  Gender 
 
Table 2: Multiple regression analysis report at t30: 
R² adjusted = 0,111 ; F(1,106)= 13,25 ; p<0,001 ; constanf coefficient = 275,79 
Independent variable  Stand Err P-value 
Glycemia t0 0,73 0,20 0,0004 
Not included in the model 
  Maximal temp t30 
  BMI 
  Gender 
 
Discussion: 
Our data show that the temperature of the dialysate intensifies the hyperglycemia seen during the initial phase of HIPEC.   
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